Clinical trial finds stem cell brain transplants feasible for Parkinson's disease
The first-year data showed no unexpected safety concerns, while imaging indicated graft survival and most participants reduced dopaminergic medication.
- Clinical data presented at the International Society for Stem Cell Research meeting showed transplanted human neural progenitor cells survived for at least one year in 13 patients with retinitis pigmentosa.
- Retinitis pigmentosa is a group of inherited retinal diseases causing progressive vision loss with no current treatment; thousands of different genetic mutations make developing mutation-specific gene therapies challenging.
- The Phase 1/2a study funded by the California Institute for Regenerative Medicine administered either 300,000 or 1,000,000 CNS10-NPC cells to participants monitored for 12 months to assess safety and feasibility.
- Investigators reported the treatment was well tolerated with a favorable safety profile, and imaging confirmed that transplanted cells remained present in the subretinal space for at least one year.
- Dr. Liao, the clinical lead, stated "the next critical question is whether these surviving cells can slow the continued deterioration that occurs in retinitis pigmentosa," while newer research explores scalable iPSC-derived neural progenitor products.
8 Articles
8 Articles
Two clinical trials based on the transplantation of neurons from stem cells completed twelve months of observation in patients with Parkinson's disease, providing new data on the safety of procedures and the possibility of using dopamine cells to replace those destroyed by the disease. The results were presented at the annual congress of the [...] The article Parkinson's, stem neurons pass the safety test. Studies with different strategies come …
Data demonstrate 1-year survival of stem cell-derived neural progenitor cells in patients with retinitis pigmentosa
New, previously unpublished clinical data have been presented at ISSCR 2026 demonstrating that transplanted human neural progenitor cells survived for at least one year following subretinal transplantation in patients with retinitis pigmentosa (RP), while maintaining a favorable safety profile.
Doctors implant dopamine-producing stem cells in Parkinson’s patients
A groundbreaking clinical trial is testing whether specially engineered stem cells can help the brain restore its own dopamine production in people with Parkinson’s disease. Because the condition is driven by the gradual loss of dopamine-producing cells—leading to tremors, stiffness, and slowed movement—researchers are implanting lab-grown cells directly into the brain’s movement center to replace what’s been lost.
Stem Cell Therapy Shows One-Year Survival in Retinitis Pigmentosa Patients
At ISSCR 2026, groundbreaking clinical data revealed the long-term survival of human neural progenitor cells transplanted into patients with retinitis pigmentosa (RP), marking a pivotal advance in retinal disease research. The study demonstrated that CNS10-NPC cells, derived from fetal brain cortex, survived in the subretinal space for at least one year without significant safety concerns, offering new hope for a disorder that currently lacks ef…
Stem Cell Therapy Shows Promise in First Human Parkinson’s Disease Trial
A landmark Phase I/II clinical study led by researchers at Skåne University Hospital and Lund University has shown that transplanting stem-cell-derived dopamine progenitor cells into the brain is feasible. Eight patients with Parkinson’s disease (PD) received transplants of STEM-PD, a cryopreserved, off-the-shelf dopaminergic progenitor product derived from human pluripotent stem cells. The three-year Phase I/II, open-label, multicenter, single-…
Coverage Details
Bias Distribution
- 75% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
